Inactive Instrument

ERBA Diagnostics, Inc.

Equities

ERBA

US29490B1017

Medical Equipment, Supplies & Distribution

ERBA Diagnostics, Inc. to Launch Lisa XL System in Europe and International Markets

November 15, 2015 at 01:06 pm

ERBA Diagnostics, Inc. will be introducing the new fully automated diagnostic testing instruments, the LISA XL ELISA Processor and Reader for Auto Immune and Infectious disease diagnostics, to the European and international markets at MEDICA 2015, the World Forum for Medicine, in Dusseldorf, Germany Nov. 16-19. The company will also feature its entire product range, including, Chemistry Analyzers, Hematology analyzers, Urine Analyzers, Hb A1c Analysers and Coagulation systems. The LISA XL, a fully automated 6 plate ELISA Processor and Reader, is a continuous loading system with 285 patient sample capacity, supported with the complete range of assays for Autoimmune and Infectious disease diagnostics.

Latest news about ERBA Diagnostics, Inc.

Inovabio S.r.l., Redix Consulting Limited Liability Company and Kolodziejczyk Waldemar acquired Delta Bialogiclas Srl from ERBA Diagnostics, Inc. for €0.05 million.	20-07-05	CI
ERBA Diagnostics, Inc. Appoints Jean Felix Lacroix as Chief Financial Officer and Treasurer, Principal Financial Officer and Principal Accounting Officer	19-04-23	CI
ERBA Diagnostics, Inc. announced that it expects to receive $8 million in funding from ERBA Diagnostics Mannheim GmbH	18-07-30	CI
ERBA Diagnostics, Inc. announced that it has received $0.75 million in funding from ERBA Diagnostics Mannheim GmbH	18-04-17	CI
Erba Diagnostics Inc. Enters into a Promissory Note in Favor of Erba Diagnostics Mannheim GmbH	18-03-01	CI
ERBA Diagnostics, Inc. announced that it has received $0.25 million in funding from ERBA Diagnostics Mannheim GmbH	17-09-27	CI
ERBA Diagnostics, Inc. Announces Management Changes, Effective August 1, 2017	17-07-25	CI
ERBA Diagnostics, Inc. Announces Board Changes	17-07-17	CI
ERBA Diagnostics, Inc. Announces Resignation of Ernesina Scala as Chief Financial Officer	17-06-22	CI
Hayden Jeffreys to Resign as Interim Chief Executive Officer and Member of Board of Directors of ERBA Diagnostics, Inc., Effective September 11, 2017	17-06-16	CI
ERBA Diagnostics, Inc. announced that it expects to receive $0.75 million in funding from ERBA Diagnostics Mannheim GmbH	17-06-15	CI
ERBA Diagnostics, Inc. Secures Revolving Credit Facility of Up to $5,000,000 from Citibank, N.A	17-05-19	CI
ERBA Diagnostics, Inc. Enters into Amended and Restated Promissory Note with Citibank	16-12-30	CI
ERBA Diagnostics, Inc. Enters into Promissory Note for an Unsecured Loan of Up to $1,000,000	16-12-02	CI
ERBA Diagnostics, Inc. Announces Management Changes	16-11-29	CI
ERBA Diagnostics, Inc. announced that it has received $0.4 million in funding from ERBA Diagnostics Mannheim GmbH	16-11-27	CI
ERBA Diagnostics, Inc.(OTCPK:ERBA) dropped from S&P TMI Index	16-10-04	CI
ERBA Diagnostics, Inc. Announces Management Changes	16-05-31	CI
ERBA Diagnostics, Inc. Changes in Terms Agreement with Citibank	16-02-23	CI
ERBA Diagnostics, Inc. announced that it has received $15 million in funding from ERBA Diagnostics Mannheim GmbH.	15-12-28	CI
ERBA Diagnostics Seeks Acquisition	15-11-30	CI
ERBA Diagnostics, Inc. to Launch Lisa XL System in Europe and International Markets	15-11-15	CI
ERBA Diagnostics, Inc. Enters into Business Loan Agreement with Citibank, N.A	15-09-22	CI
ERBA Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-08	CI
ERBA Diagnostics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-06-26	CI

Chart ERBA Diagnostics, Inc.

Duration

Period

More charts

Company Profile

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B

Other Medical Equipment, Supplies & Distribution